AbbVievsMonte Rosa Therapeutics

ABBV and GLUE stock compared: price, dividend, valuation and results, from SEC filings.

GLUE

Monte Rosa Therapeutics, Inc.

$9.16

Value $783M

-2.24%
GLUE's page

AbbVie (ABBV) has a market value of $521B and Monte Rosa Therapeutics (GLUE) $783M. Over the last year, with dividends, ABBV moved +30.6% and GLUE -36.2%. Dividend yield: ABBV 2.35%, GLUE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    GLUE$783M

    ABBV is 665 times GLUE

  • Revenue, 12 months

    ABBV$66.0B

    GLUE$70M

    ABBV is 939 times GLUE

  • Net income, 12 months

    ABBV$10.3B

    GLUE-$131M

  • Operating margin

    ABBV32.2%

    GLUE-214.5%

    246.7 points apart

  • ROIC

    ABBV25.7%

    GLUE-30.0%

    55.7 points apart

  • P/E

    ABBV50.6

    GLUE–

  • Dividend yield

    ABBV2.4%

    GLUE0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.4%

    GLUE-60.2%

    261.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.4%

GLUE-60.2%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsGLUEWith dividends
1 year since November 14, 2025+30.6%Price +26.8%-36.2%Price -36.2%
3 years since November 16, 2023+135.5%+33.0% a yearPrice +113.0%+182.7%+41.4% a yearPrice +182.7%
5 years since November 15, 2021+201.4%+24.7% a yearPrice +152.1%-60.2%-16.8% a yearPrice -60.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieGLUEMonte Rosa Therapeutics

Valuation

ABBVGLUE
Valuation
Price$294.55$9.16
Market value$521B$783M
Enterprise value (EV)$591B$205M
P/E50.6–
P/E, 5-year median57.0–
P/B–1.6
EV/EBIT27.8–
Free cash flow yield3.6%–

Results and growth

ABBVGLUE
Results and growth
Revenue, 12 months$66.0B$70M
Net income, 12 months$10.3B-$131M
Free cash flow, 12 months$18.9B-$174M
Earnings per share, 12 months$5.81-$1.64
Revenue growth, year on year8.6%63.5%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVGLUE
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-214.5%
Net margin15.7%-186.2%
ROIC25.7%-30.0%
ROE–-33.0%

Balance sheet

ABBVGLUE
Balance sheet
Cash$10.8B$578M
Total debt$80.9B$36M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVGLUE
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or GLUE

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Monte Rosa Therapeutics?

By market value, AbbVie ($521B) is about 665.4 times Monte Rosa Therapeutics ($783M), at today's prices.

How did ABBV and GLUE stock do over the last 5 years?

Since November 15, 2021, ABBV's price moved +152.1% and GLUE's -60.2%. With dividends: ABBV +201.4% (+24.7% a year), GLUE -60.2% (-16.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or GLUE?

The dividend yield at today's price is 2.35% for AbbVie and none for Monte Rosa Therapeutics. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Monte Rosa Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and -186.2% for Monte Rosa Therapeutics, and the operating margin 32.2% and -214.5%. Revenue was $66.0B and $70M.

Which is the better investment, AbbVie or Monte Rosa Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.